187 related articles for article (PubMed ID: 38057405)
21. Identification of the Immune Signatures for Ovarian Cancer Based on the Tumor Immune Microenvironment Genes.
Shen X; Gu X; Ma R; Li X; Wang J
Front Cell Dev Biol; 2022; 10():772701. PubMed ID: 35372348
[TBL] [Abstract][Full Text] [Related]
22. Establishment of an ovarian cancer omentum metastasis-related prognostic model by integrated analysis of scRNA-seq and bulk RNA-seq.
Zhang D; Lu W; Cui S; Mei H; Wu X; Zhuo Z
J Ovarian Res; 2022 Nov; 15(1):123. PubMed ID: 36424614
[TBL] [Abstract][Full Text] [Related]
23. Identification of SHCBP1 as a potential biomarker involving diagnosis, prognosis, and tumor immune microenvironment across multiple cancers.
Wang N; Zhu L; Wang L; Shen Z; Huang X
Comput Struct Biotechnol J; 2022; 20():3106-3119. PubMed ID: 35782736
[TBL] [Abstract][Full Text] [Related]
24. The Cancer-Associated Fibroblasts-Related Gene COMP Is a Novel Predictor for Prognosis and Immunotherapy Efficacy and Is Correlated with M2 Macrophage Infiltration in Colon Cancer.
Ma H; Qiu Q; Tan D; Chen Q; Liu Y; Chen B; Wang M
Biomolecules; 2022 Dec; 13(1):. PubMed ID: 36671447
[TBL] [Abstract][Full Text] [Related]
25. Identifies microtubule-binding protein
Wang W; Zhang J; Wang Y; Xu Y; Zhang S
Comput Struct Biotechnol J; 2022; 20():3322-3335. PubMed ID: 35832625
[TBL] [Abstract][Full Text] [Related]
26. Combination of tumor mutation burden and immune infiltrates for the prognosis of lung adenocarcinoma.
Zhao Z; He B; Cai Q; Zhang P; Peng X; Zhang Y; Xie H; Wang X
Int Immunopharmacol; 2021 Sep; 98():107807. PubMed ID: 34175739
[TBL] [Abstract][Full Text] [Related]
27. Identification and validation of cancer-associated fibroblast-related subtypes and the prognosis model of biochemical recurrence in prostate cancer based on single-cell and bulk RNA sequencing.
Li T; Zhou Z; Xie Z; Fan X; Zhang Y; Zhang Y; Song X; Ruan Y
J Cancer Res Clin Oncol; 2023 Oct; 149(13):11379-11395. PubMed ID: 37369799
[TBL] [Abstract][Full Text] [Related]
28. Efficacy of immune checkpoint inhibitor monotherapy or combined with other small molecule-targeted agents in ovarian cancer.
Muaibati M; Abuduyilimu A; Zhang T; Dai Y; Li R; Huang F; Li K; Tong Q; Huang X; Zhuang L
Expert Rev Mol Med; 2023 Jan; 25():e6. PubMed ID: 36691778
[TBL] [Abstract][Full Text] [Related]
29. Prognostic analysis of lung adenocarcinoma based on cancer-associated fibroblasts genes using scRNA-sequencing.
Zhang H; Wang Y; Wang K; Ding Y; Li X; Zhao S; Jia X; Sun D
Aging (Albany NY); 2023 Jul; 15(14):6774-6797. PubMed ID: 37437244
[TBL] [Abstract][Full Text] [Related]
30. Identification of an Autophagy-Related Signature for Prognosis and Immunotherapy Response Prediction in Ovarian Cancer.
Ding J; Wang C; Sun Y; Guo J; Liu S; Cheng Z
Biomolecules; 2023 Feb; 13(2):. PubMed ID: 36830707
[TBL] [Abstract][Full Text] [Related]
31. Construction and validation of a bladder cancer risk model based on autophagy-related genes.
Shen C; Yan Y; Yang S; Wang Z; Wu Z; Li Z; Zhang Z; Lin Y; Li P; Hu H
Funct Integr Genomics; 2023 Jan; 23(1):46. PubMed ID: 36689018
[TBL] [Abstract][Full Text] [Related]
32. Oxidative Stress Response Biomarkers of Ovarian Cancer Based on Single-Cell and Bulk RNA Sequencing.
Zheng M; Hu Y; Liu O; Li S; Wang Y; Li X; Liu J; Yang Q; Li X; Lin B
Oxid Med Cell Longev; 2023; 2023():1261039. PubMed ID: 36743693
[TBL] [Abstract][Full Text] [Related]
33. Prognostic and Immunological Significance of CXCR2 in Ovarian Cancer: A Promising Target for Survival Outcome and Immunotherapeutic Response Assessment.
Ji H; Ren M; Liu T; Sun Y
Dis Markers; 2021; 2021():5350232. PubMed ID: 34840630
[TBL] [Abstract][Full Text] [Related]
34. Targeting cancer-associated fibroblast-secreted WNT2 restores dendritic cell-mediated antitumour immunity.
Huang TX; Tan XY; Huang HS; Li YT; Liu BL; Liu KS; Chen X; Chen Z; Guan XY; Zou C; Fu L
Gut; 2022 Feb; 71(2):333-344. PubMed ID: 33692094
[TBL] [Abstract][Full Text] [Related]
35. A novel extrachromosomal circular DNA related genes signature for overall survival prediction in patients with ovarian cancer.
Zhang Y; Dong K; Jia X; Du S; Wang D; Wang L; Qu H; Zhu S; Wang Y; Wang Z; Zhang S; Sun W; Fu S
BMC Med Genomics; 2023 Jun; 16(1):140. PubMed ID: 37337170
[TBL] [Abstract][Full Text] [Related]
36. The Efficacy of Tumor Mutation Burden as a Biomarker of Response to Immune Checkpoint Inhibitors.
Moeckel C; Bakhl K; Georgakopoulos-Soares I; Zaravinos A
Int J Mol Sci; 2023 Apr; 24(7):. PubMed ID: 37047684
[TBL] [Abstract][Full Text] [Related]
37. Comprehensive Analysis Identifies PI3K/Akt Pathway Alternations as an Immune-Related Prognostic Biomarker in Colon Adenocarcinoma Patients Receiving Immune Checkpoint Inhibitor Treatment.
Lin A; Gu T; Hu X; Zhang J; Luo P
J Immunol Res; 2022; 2022():8179799. PubMed ID: 35707003
[TBL] [Abstract][Full Text] [Related]
38. A prognostic model based on immune-related long noncoding RNAs for patients with epithelial ovarian cancer.
Peng Y; Wang H; Huang Q; Wu J; Zhang M
J Ovarian Res; 2022 Jan; 15(1):8. PubMed ID: 35031063
[TBL] [Abstract][Full Text] [Related]
39. Robust Prediction of Immune Checkpoint Inhibition Therapy for Non-Small Cell Lung Cancer.
Jiang J; Jin Z; Zhang Y; Peng L; Zhang Y; Zhu Z; Wang Y; Tong D; Yang Y; Wang J; Yang Y; Xiao K
Front Immunol; 2021; 12():646874. PubMed ID: 33927719
[TBL] [Abstract][Full Text] [Related]
40. Functional enrichment analysis of LYSET and identification of related hub gene signatures as novel biomarkers to predict prognosis and immune infiltration status of clear cell renal cell carcinoma.
Chen Y; He J; Jin T; Zhang Y; Ou Y
J Cancer Res Clin Oncol; 2023 Dec; 149(18):16905-16929. PubMed ID: 37740762
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
